Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	135558-11-1
Formula :	C₉H₁₈N₂O₃Pt
M.W :	397.33
SMILES Code :	CC([O-]1)C([O-][Pt]21[NH2+]CC(CC3)C3C[NH2+]2)=O
Synonyms :	D-19466
MDL No. :	MFCD00866545

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

SMMC7721 cells	1.536 µg/mL	117.2 hours	To investigate the radiosensitization effect of LBP on SMMC7721 cells, results showed that LBP significantly increased 125I-induced apoptosis.	Cell Death Dis. 2019 Oct 3;10(10):744
HepG2 cells	5.972 µg/mL	117.2 hours	To investigate the radiosensitization effect of LBP on HepG2 cells, results showed that LBP significantly increased 125I-induced apoptosis.	Cell Death Dis. 2019 Oct 3;10(10):744
SOSP-9607	7.94 µg/mL (SOSP-9607-Vector) and 10.04 µg/mL (SOSP-9607-FUBP1)	24 hours	To investigate the effect of FUBP1 overexpression on the sensitivity of SOSP-9607 cells to Lobaplatin. Results showed that FUBP1 overexpression increased the resistance of SOSP-9607 cells to Lobaplatin.	MedComm (2020). 2023 May 9;4(3):e257
MG63	14.95 µg/mL (MG63-Vector) and 28.36 µg/mL (MG63-FUBP1)	24 hours	To investigate the effect of FUBP1 overexpression on the sensitivity of MG63 cells to Lobaplatin. Results showed that FUBP1 overexpression increased the resistance of MG63 cells to Lobaplatin.	MedComm (2020). 2023 May 9;4(3):e257
HCT116 cells	0, 8, 16, 32 μg/ml	8 hours	To investigate the effect of Lobaplatin on the viability of HCT116 cells and its induction of pyroptosis. Results showed that Lobaplatin inhibited cell viability in a dose-dependent manner and induced cell swelling and large bubbles emerging from the plasma membrane, with TEM revealing multiple pores in the membrane.	Cell Death Dis. 2019 Feb 25;10(3):193
HT-29 cells	0, 8, 16, 32 μg/ml	8 hours	To investigate the effect of Lobaplatin on the viability of HT-29 and HCT116 cells and its induction of pyroptosis. Results showed that Lobaplatin inhibited cell viability in a dose-dependent manner and induced cell swelling and large bubbles emerging from the plasma membrane, with TEM revealing multiple pores in the membrane.	Cell Death Dis. 2019 Feb 25;10(3):193
SaOS-2 osteosarcoma cells	10 μg/mL	24 hours	To investigate the effect of rhIL-6 intervention on Lobaplatin resistance, results showed that rhIL-6 pretreatment reduced the sensitivity of osteosarcoma cells to Lobaplatin.	Cancer Cell Int. 2021 Oct 30;21(1):581
MCF-7 cells	5, 10, 50 mg/L	24 hours	To investigate the effect of lobaplatin on MCF-7 cell proliferation and apoptosis. Results showed that lobaplatin significantly reduced cell proliferation and increased cell apoptotic percentage.	Drug Des Devel Ther. 2018 Oct 29;12:3563-3571
Y79 retinoblastoma cells	5, 10, 20, 40 µg/ml	24, 48, 72 hours	To evaluate the inhibitory effect of lobaplatin on Y79 cell proliferation, results showed that lobaplatin significantly inhibited cell proliferation in a dose- and time-dependent manner and induced apoptosis.	Int J Oncol. 2020 Sep;57(3):697-706

Nude mice	Osteosarcoma xenograft model	Subcutaneous injection	3 mg/kg	Every 3 days for 6 weeks	Evatanepag, as an EP2 receptor agonist, was used to stimulate the arachidonic acid metabolic pathway in FUBP1-silenced osteosarcoma cells to verify that FUBP1 promotes lobaplatin resistance in osteosarcoma cells through PTGES and the arachidonic acid metabolic pathway.	MedComm (2020). 2023 May 9;4(3):e257
Nude mice	Subcutaneous xenograft model	Intraperitoneal injection	3 mg/kg	Every 3 days for 6 weeks	To investigate the effect of FUBP1 on Lobaplatin resistance in vivo. Results showed that FUBP1 overexpression increased tumor resistance to Lobaplatin, while FUBP1 knockdown increased tumor sensitivity to Lobaplatin.	MedComm (2020). 2023 May 9;4(3):e257
BALB/c nude mice	Subcutaneous xenograft tumor model	Intraperitoneal injection	11 mg/kg	Tumor volume was monitored every 3 days, and mice were sacrificed at the end of the experiment	To investigate the inhibitory effect of Lobaplatin on colon cancer xenograft tumors. Results showed that Lobaplatin significantly inhibited tumor growth, and GSDME knockout did not affect the inhibitory effect of Lobaplatin on tumor formation.	Cell Death Dis. 2019 Feb 25;10(3):193
BALB/c nude mice	Y79 retinoblastoma xenograft model	Tail vein injection	750 µg/kg	Every 3 days for 1 or 2 weeks	To evaluate the inhibitory effect of lobaplatin on Y79 xenograft tumors, results showed that lobaplatin significantly inhibited tumor growth and was more effective than carboplatin.	Int J Oncol. 2020 Sep;57(3):697-706

{[proInfo.proName]}

CAS No.: 135558-11-1

{[proInfo.proName]}

CAS No.: 135558-11-1

Alternative Products

Product Details of Lobaplatin

Safety of Lobaplatin

Related Pathways of Lobaplatin

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT03731442	Esophageal Cancer	Phase 3	Recruiting	October 31, 2027	China, Beijing ... More >> Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) Recruiting Beijing, Beijing, China, 100021 Contact: Zefen Xiao, MD Less <<
NCT03328234	IMRT With or Without Concurren... More >>t Chemotherapy for Esophageal Cancer Less <<	Phase 3	Recruiting	December 31, 2022	China ... More >> Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) Recruiting Beijing, China, 100021 Contact: Xin Wang, MD +861013311583220 beryl_wx2000@163.com Less <<
NCT03308552	Esophageal Neoplasms	Phase 3	Recruiting	August 30, 2021	China, Beijing ... More >> Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) Recruiting Beijing, Beijing, China, 100021 Contact: Zefen Xiao, MD Less <<
NCT02856126	Hepatocellular Carcinoma	Phase 3	Recruiting	August 2018	China, Guangdong ... More >> Dongguan People's Hospital Recruiting Dongguan, Guangdong, China, 523059 Contact: Wusheng Yu, MD 13827285010 yuwusheng1998@126.com Cancer Center Sun Yat-sen University Recruiting Guangzhou, Guangdong, China, 510060 Contact: Ming Shi, MD 8620-87343115 shiming@mail.sysu.edu.cn The First Affiliated Hospital, Sun Yat-sen University Recruiting Guangzhou, Guangdong, China, 510060 Contact: Guosheng Tan, MD 13725254145 tgs1976@163.com Guangzhou Twelfth People 's Hospital Recruiting Guangzhou, Guangdong, China, 510620 Contact: Yuanmin Zhou, MD 15521278919 13430288977@139.com Principal Investigator: Jinghua Chen, MD Kaiping Central Hospital Recruiting Kaiping, Guangdong, China, 529300 Contact: Shijie Zhang, MD 13717287622 Shijie_9262511@163.com China, Hunan The First Affiliated Hospital of University Of South China Recruiting Hengyang, Hunan, China, 421001 Contact: Xiaoping Wu, MD 13975486015 wxp19730806@sina.com China, Shanxi The First Affiliated Hospital Of Xi'an Jiaotong University Recruiting Xi'an, Shanxi, China, 710061 Contact: Xin Zheng, MD 13649265446 183421344@qq.com Less <<
NCT01229839	Hepatocellular Carcinoma	Phase 3	Unknown	August 2018	China, Guangdong ... More >> Cancer Center Sun Yat-sen University Recruiting Guangzhou, Guangdong, China Contact: Ming Shi, MD 86-2087343582 ext 86-2087343582 shiming@mail.sysu.edu.cn Contact: Rong Ping Guo, MD 86-2087343117 ext 86-2087343117 guorongp@mail.sysu.edu.cn Principal Investigator: Ming Shi, MD Less <<
NCT01259414	Hepatocellular Carcinoma	Phase 3	Unknown	January 2017	China, Guangdong ... More >> Cancer Center Sun Yat-sen University Recruiting Guangzhou, Guangdong, China Contact: Ming Shi 86-2087343582 ext 86-2087343582 shiming@mail.sysu.edu.cn Contact: Ping Rong Guo 86-2087343117 ext 86-2087343117 guorongp@mail.sysu.edu.cn Principal Investigator: Ming Shi Less <<
NCT02435953	Hepatocellular Carcinoma ... More >> Chemoembolization, Therapeutic Ablation Techniques, RFA Less <<	Phase 4	Recruiting	-	China, Guangdong ... More >> Minimally Invasive Interventional Division, Medical Imaging Center, Sun Yat-sen University Cancer Center, Recruiting Guangzhou, Guangdong, China, 500060 Contact: Ming Zhao, doctor +86 020 87343272 zhaoming@sysucc.org.cn Contact: Tao Pan, doctor +86 020 87343271 pantao0909@hotmail.com Less <<
NCT02973685	HepatoCellular Carcinoma	Phase 3	Recruiting	October 2019	China, Guangdong ... More >> Dongguan People's Hospital Recruiting Dongguan, Guangdong, China, 523059 Contact: Wusheng Yu, MD 13827285010 yuwusheng1998@126.com Cancer Center Sun Yat-sen University Recruiting Guangzhou, Guangdong, China, 510060 Contact: Ming Shi, MD 8620-87343115 shiming@mail.sysu.edu.cn The First Affiliated Hospital, Sun Yat-sen University Recruiting Guangzhou, Guangdong, China, 510060 Contact: Guosheng Tan, MD 13725254145 tgs1976@163.com Guangzhou Twelfth People's Hospital Recruiting Guangzhou, Guangdong, China, 510620 Contact: Yuanmin Zhou, MD 15521278919 13430288977@139.com Principal Investigator: Jinghua Chen, MD Kaiping Central Hospital Recruiting Kaiping, Guangdong, China, 529300 Contact: Shijie Zhang, MD 13717287622 Shijie_9262511@163.com China, Hunan The First Affiliated Hospital of University Of South China Recruiting Hengyang, Hunan, China, 421001 Contact: Xiaoping Wu, MD 13975486015 wxp19730806@sina.com China, Shanxi The First Affiliated Hospital Of Xi'an Jiaotong University Recruiting Xi'an, Shanxi, China, 710061 Contact: Xin Zheng, MD 13649265446 183421344@qq.com Less <<
NCT03048123	Hepatocellular Carcinoma	Phase 2	Completed	-	China, Guangdong ... More >> Cancer Center Sun Yat-sen University Guangzhou, Guangdong, China, 510060 Less <<
NCT02430974	Carcinoma, Non-Small-Cell Lung	Phase 2	Unknown	January 2018	-
NCT03196869	Locally Advanced Head and Neck... More >> Squamous Cell Carcinoma Less <<	Phase 2	Recruiting	August 12, 2022	China, Guizhou ... More >> Cancer Hospital of Guizhou Medical University Recruiting Guiyang, Guizhou, China, 550000 Contact: Feng Jin, Bachelor 0851-86512802 jinf8865@yahoo.com.cn Sub-Investigator: Weili Wu, master Sub-Investigator: Jinhua Long, master Sub-Investigator: Yuanyuan Li, master Sub-Investigator: Xiuyun Gong, Bachelor Sub-Investigator: Xiaoxiao Chen, Bachelor Sub-Investigator: Juan Li, Bachelor Less <<
NCT03349827	Peritoneal Metastases From Gas... More >>tric Cancer Less <<	Not Applicable	Recruiting	November 30, 2020	China, Hubei ... More >> Wuhan University Recruiting Wuhan, Hubei, China Contact: Bin Xiong +86 27 67813152 jyn1983@163.com Less <<
NCT02301091	Hepatocellular Carcinoma	Phase 3	Recruiting	October 2019	China, Guangdong ... More >> Minimally Invasive Interventional Division, Medical Imaging Center, Sun Yat-sen University Cancer Center, Recruiting Guangzhou, Guangdong, China, 500060 Contact: Ming Zhao, doctor +86 020 87343272 zhaoming@sysucc.org.cn Less <<
NCT01869088	Hepatocellular Carcinoma	Phase 3	Active, not recruiting	January 2018	China, Guangdong ... More >> Cancer Center Sun Yat-sen University Guangzhou, Guangdong, China Less <<
NCT02678806	HepatoCellular Carcinoma	Not Applicable	Recruiting	November 1, 2022	China, Guangxi ... More >> TaoBai Recruiting Nanning, Guangxi, China, 530000 Contact: Bai Tao, MD +86 13878862632 25859373@qq.com Less <<
NCT02972320	Extensive Stage Small Cell Lun... More >>g Cancer Less <<	Phase 2	Unknown	December 2018	China, Liaoning ... More >> The First Affiliated Hospital of China Medical University Recruiting Shenyang, Liaoning, China, 110001 Contact: mingfang zhao, professor 13644055129 Less <<
NCT03606239	Carcinoma, Non-Small-Cell Lung	Not Applicable	Not yet recruiting	July 1, 2024	-
NCT00646100	Hepatocellular Carcinoma	Phase 4	Completed	-	China, Guangdong ... More >> Cancer Canter Sun Yat-Sen University Guangzhou, Guangdong, China, 510060 Less <<
NCT03413436	Esophageal Cancer	Phase 4	Not yet recruiting	February 21, 2018	China, Henan ... More >> Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university ZhengZhou, Henan, China, 450008 Less <<
NCT03221608	Colorectal Neoplasms	Phase 3	Not yet recruiting	August 1, 2024	-
NCT03371693	Ovarian Cancer ... More >> Ovary Neoplasm Ovarian Neoplasms Epithelial Ovarian Cancer Ovarian Cancer, Epithelial Hyperthermic Intraperitoneal Chemotherapy(HIPEC) Less <<	Phase 3	Active, not recruiting	December 30, 2020	China, Hubei ... More >> Zhongnan Hospital of Wuhan University Wuhan, Hubei, China, 430072 Less <<
NCT01851746	-		Unknown	February 2015	China, Hubei ... More >> Zhongnan Hospital of Wuhan University Wuhan, Hubei, China, 430071 Less <<
NCT03117257	Locally Advanced Head and Neck... More >> Squamous Cell Carcinoma Less <<	Phase 2	Recruiting	August 20, 2021	China, Guizhou ... More >> Cancer Hospital of Guizhou Medical University Recruiting Guiyang, Guizhou, China, 550000 Contact: Feng Jin, Bachelor 0851-86512802 jinf8865@yahoo.com.cn Sub-Investigator: Weili Wu, master Sub-Investigator: Jinhua Long, master Sub-Investigator: Yuanyuan Li, master Sub-Investigator: Xiuyun Gong, Bachelor Sub-Investigator: Xiaoxiao Chen, Bachelor Sub-Investigator: Mang Zhang, Bachelor Less <<
NCT01034683	Esophageal Carcinoma	Phase 3	Unknown	December 2010	China, Shandong ... More >> Taian Cancer Hospital Taian, Shandong, China, 271000 Less <<
NCT03188497	Acute Toxic Effects ... More >> Tumor Responses Less <<	Phase 1	Completed	-	China, Guangdong ... More >> the Fifth Hospital Affiliated to Sun Yat-Sen University Zhuhai, Guangdong, China, 519000 Less <<
NCT03613753	Small-cell Lung Cancer	Phase 2	Recruiting	June 1, 2021	China, Guizhou ... More >> The affiliated hospital of Guizhou medical university Recruiting Guiyang, Guizhou, China, 550004 Contact: Shengfa Su, PhD,MD 86-13608550432 sushengfa2005@163.com Less <<
NCT01483300	Breast Cancer	Phase 2	Unknown	November 2014	China, Heilongjiang ... More >> Cancer Hospital of Harbin Medical University Recruiting Harbin, Heilongjiang, China, 150081 Contact: Qingyuan Zhang, MD 86-451-86298276 zhma19650210@163.com Contact: Xinmei Kang, MD 86-451-86298683 kxm791107@163.com Principal Investigator: Qingyuan Zhang, MD Sub-Investigator: Xinmei Kang, MD Less <<
NCT03613597	Small-cell Lung Cancer	Phase 2	Recruiting	January 1, 2022	China, Guizhou ... More >> The affiliated hospital of Guizhou medical university Recruiting Guiyang, Guizhou, China, 550004 Contact: Shengfa Su, PhD,MD 86-13608550432 sushengfa2005@163.com Less <<
NCT02099396	Lobaplatin and Gemcitabine in ... More >>Combination, Second-line Treatments on Advanced Osteosarcoma Less <<	Phase 2 Phase 3	Unknown	-	-
NCT03700359	Small Cell Lung Carcinoma	Phase 2	Not yet recruiting	November 29, 2021	-
NCT03210389	Recurrent Nasopharyngeal Carci... More >>noma Less <<	PHASE2	UNKNOWN	2025-12-21	Department of Radiation Oncolo... More >>gy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510000, China Less <<
NCT00493402	Hepatocellular Carcinoma	Phase 3	Completed	-	China, Guangdong ... More >> Cancer Center Sun Yat-sen University Guangzhou, Guangdong, China, 510060 Less <<
NCT01350206	Hepatocellular Carcinoma With ... More >>PVTT Less <<	Phase 4	Unknown	May 2013	China, Guangdong ... More >> Cancer Center Sun Yat-sen University Recruiting Guangzhou, Guangdong, China, 510060 Contact: Min-Shan Chen, M.D. Ph.D. (8620) 8734 3117 Chminsh@mail.sysu.edu.cn Principal Investigator: min-shan chen, M.D.,Ph.D. Less <<

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	2.52mL 0.50mL 0.25mL	12.58mL 2.52mL 1.26mL	25.17mL 5.03mL 2.52mL
Dissolving Methods	Animal experiment The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed